RESPIRI *LIMITED*

RESPIRI COMPLETES CORE SOFTWARE PLATFORM

Melbourne, Australia 31 January 2017 – Respiri Limited is pleased to announce the completion of its core technology software platform and the latest generation of the AirSonea® smartphone app designed to help asthmatics better monitor and manage their asthma, stay in control of symptoms and feel well so they can lead a full and active life.

Respiri's primary focus for the remainder of the year is the completion of partnership transactions. This core technology is an essential component of negotiations. Recent partner discussions and transactions overseas involving prescription smart inhalers for medication compliance, emphasise the value of leading edge digital technology to empower patients and physicians.

This core technology also provides the basis for the development of the state of the art wireless overnight monitoring product overseen by Professor Zahra Moussavi of the University of Manitoba who visited Melbourne during January.

AirSonea's Health Chart clearly shows the correlation between WheezeRATE, adherence to medication schedule (green dot), symptoms & triggers (red dot) and the effectiveness of reliever medication (yellow dot).

This example shows spikes in the WheezeRATE when the preventer medication has been missed. After the user takes their reliever, the WheezeRATE drops.

Engaging Consumer Interface

Using sensors, proprietary algorithms and analytics to quickly, easily and objectively measure the major symptom of asthma, wheeze, the latest generation AirSonea app allows users to set preventer medication reminders, log symptoms, allergic triggers and reliever medication doses.

The AirSonea app lets patients view all trends and graphs seamlessly so the relationship between asthma symptoms and triggers and response to medication can be understood in an instant.

Integrate into Clinical Practices

Physician currently lack the tools to understand how their patients are doing between visits and adjust therapy. The AirSonea apps' diary features provide healthcare professionals with invaluable data to help in the design of essential asthma action plans. Wheeze measurements and diary data are automatically sent over WiFi to the secure Respiri Cloud where users can access, track and share their results.

Physicians assess recent asthma control by reviewing symptoms between visits. With the AirSonea app, the patient and carer do not need to remember the details, which can be challenging. Time and date stamped data, with graphs showing the correlation between asthma events, allergic triggers and medication use for any given period is available in a single tap.

The physicians can observe if preventer medication has been missed should a high wheeze measurement be recorded and will also see if reliever medication has been effective with wheeze measurement dropping following a dose. Both patient and doctor will also better understand the individual's allergic triggers and together, devise ways to avoid these triggers for better symptom control.

Every patient's asthma is different. AirSonea, available without prescription and over the counter, will change the way asthma patients monitor and manage their condition by empowering them and their healthcare professionals with the data they need to get a better understanding of how asthma affects them.

Leon L'Huillier
Executive Chairman

Ph: 1800 476 632